Moderna and the european commission (ec) amend covid-19 vaccine agreement to supply omicron-containing bivalent candidates; ec purchases additional 15 million doses

Contractually remaining doses of moderna's covid-19 vaccine (spikevax, mrna-1273) will be converted to moderna's next generation omicron-containing bivalent vaccines cambridge, ma / accesswire / august 9, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced an amendment to its agreement with the european commission (ec) to convert contractually agreed doses of moderna's covid-19 vaccine (spikevax, mrna-1273) to the company's omicron-containing bivalent vaccines for supply in 2022, pending regulatory approval. in addition, the ec has agreed to purchase an additional 15 million doses of omicron-containing vaccine booster candidates from moderna.
MRNA Ratings Summary
MRNA Quant Ranking